89 related articles for article (PubMed ID: 19800119)
1. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.
Jeddi R; Ghédira H; Mnif S; Gouider E; Fenaux P; Meddeb B
Leuk Res; 2010 Apr; 34(4):545-7. PubMed ID: 19800119
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
4. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
5. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
7. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Haznedaroglu IC; Aksu S; Ozcebe OI; Turgut M; Aslan R; Ozdemir E
Leuk Res; 2010 Dec; 34(12):e317-9. PubMed ID: 20696473
[No Abstract] [Full Text] [Related]
9. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
[TBL] [Abstract][Full Text] [Related]
10. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
11. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
12. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].
Schwarz J; Korístek Z; Starý J; Zák P; Kozák T; Marková J; Michalová K; Dvoráková D; Mayer J; Cetkovský P
Vnitr Lek; 2008; 54(7-8):757-70. PubMed ID: 18780575
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
Jeddi R; Kacem K; Ben Neji H; Mnif S; Gouider E; Aissaoui L; Ben Amor R; Ben Lakhal R; Ben Abid H; Belhadjali Z; Meddeb B
Hematology; 2008 Jun; 13(3):142-6. PubMed ID: 18702871
[TBL] [Abstract][Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
16. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia.
Leblebjian H; DeAngelo DJ; Skirvin JA; Stone RM; Wadleigh M; Werner L; Neuberg DS; Bartel S; McDonnell AM
Leuk Res; 2013 Jul; 37(7):747-51. PubMed ID: 23643326
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
19. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
[TBL] [Abstract][Full Text] [Related]
20. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
